Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Myotropic antispasmodic. It inhibits PDE, causes accumulation of cAMP in the cell and reduces the content of intracellular calcium. Reduces the tone of smooth muscles of internal organs (GIT, respiratory, urinary, genital system) and blood vessels. It causes an enlargement of the arteries, promotes an increase in blood flow, incl. cerebral. Has hypotensive effect.
In high doses reduces the excitability of the heart muscle and slows intracardiac conduction.
When used in average therapeutic doses, the effect on the central nervous system is poorly expressed.
PHARMACOKINETICS
Bioavailability is 54%. Binding to plasma proteins - 90%. Well distributed in the body, penetrates through the histohematological barriers. Metabolised in the liver.
T 1/2 - 0.5-2 hours. An increase of up to 24 hours is possible.
It is excreted by the kidneys in the form of metabolites. Completely removed from the blood during dialysis.
INDICATIONS
Spasms of smooth muscles of abdominal cavity organs, bronchi, peripheral vessels, cerebral vessels, kidneys; angina pectoris (as part of combination therapy).
As an aid for premedication.
DOSING MODE
Inside - 40-60 mg 3-5 times / day. Rectally - 20-40 mg 2-3 times / day.
With a / m, p / to or in / in the introduction of a single dose for adults is 10-20 mg; the interval between administrations is not less than 4 hours. For elderly patients, the initial single dose is not more than 10 mg. For children aged 1 to 12 years, the maximum single dose is 200-300 Ојg / kg.
SIDE EFFECT
Possible: nausea, constipation, drowsiness, excessive sweating, arterial hypotension, increased activity of hepatic transaminases.
With rapid on / in the introduction, as well as when used in high doses: the development of AV-blockade, disturbances of the heart rhythm.
CONTRAINDICATIONS
AV-blockade, glaucoma, severe hepatic insufficiency, advanced age (risk of hyperthermia), children under 6 months, hypersensitivity to papaverine.
PREGNANCY AND LACTATION
During pregnancy and lactation (breastfeeding), the safety and effectiveness of papaverine is not established.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in severe hepatic insufficiency.
APPLICATION FOR CHILDREN
Contraindicated in childhood up to 6 months.
APPLICATION IN ELDERLY PATIENTS
Contraindicated in old age (risk of hyperthermia).
SPECIAL INSTRUCTIONS
Use with caution in conditions after traumatic brain injury, with chronic renal failure, with adrenal insufficiency, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, and shock states.
In / in should be administered slowly and under the supervision of a doctor.
During the treatment should be excluded from drinking alcohol.
DRUG INTERACTION
With simultaneous use with anticholinergics, anticholinergic effects may be enhanced.
It is believed that with simultaneous use with alprostadil for intracavernous administration, there is a risk of developing priapism.
There are reports of a decrease in the effectiveness of levodopa when it is used simultaneously.
Reduces the hypotensive effect of methyldopa.
